EP3723743A4 - The pharmaceutical combination comprising dapoxetine, phosphodiesterase type-5 inhibitor and anti-emetic agent - Google Patents

The pharmaceutical combination comprising dapoxetine, phosphodiesterase type-5 inhibitor and anti-emetic agent Download PDF

Info

Publication number
EP3723743A4
EP3723743A4 EP18915505.4A EP18915505A EP3723743A4 EP 3723743 A4 EP3723743 A4 EP 3723743A4 EP 18915505 A EP18915505 A EP 18915505A EP 3723743 A4 EP3723743 A4 EP 3723743A4
Authority
EP
European Patent Office
Prior art keywords
dapoxetine
inhibitor
pharmaceutical combination
phosphodiesterase type
emetic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18915505.4A
Other languages
German (de)
French (fr)
Other versions
EP3723743A2 (en
Inventor
Ali. TÜRKYILMAZ
Arzu. PALATÖKEN
Dicle. GÜNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Montero Gida Sanayi Ve Ticaret AS
Original Assignee
Montero Gida Sanayi Ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Montero Gida Sanayi Ve Ticaret AS filed Critical Montero Gida Sanayi Ve Ticaret AS
Publication of EP3723743A2 publication Critical patent/EP3723743A2/en
Publication of EP3723743A4 publication Critical patent/EP3723743A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP18915505.4A 2017-12-15 2018-12-13 The pharmaceutical combination comprising dapoxetine, phosphodiesterase type-5 inhibitor and anti-emetic agent Withdrawn EP3723743A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201720443 2017-12-15
PCT/TR2018/050806 WO2019203753A2 (en) 2017-12-15 2018-12-13 The pharmaceutical combination comprising dapoxetine, phosphodiesterase type-5 inhibitor and anti-emetic agent

Publications (2)

Publication Number Publication Date
EP3723743A2 EP3723743A2 (en) 2020-10-21
EP3723743A4 true EP3723743A4 (en) 2021-09-08

Family

ID=68240624

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18915505.4A Withdrawn EP3723743A4 (en) 2017-12-15 2018-12-13 The pharmaceutical combination comprising dapoxetine, phosphodiesterase type-5 inhibitor and anti-emetic agent

Country Status (2)

Country Link
EP (1) EP3723743A4 (en)
WO (1) WO2019203753A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023179542A1 (en) 2022-03-21 2023-09-28 Gasherbrum Bio , Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
WO2023198140A1 (en) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024125602A1 (en) 2022-12-15 2024-06-20 Gasherbrum Bio, Inc. Salts and solid forms of a compound having glp-1 agonist activity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020037828A1 (en) * 1997-10-28 2002-03-28 Wilson Leland F. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US20150202168A1 (en) * 2012-08-17 2015-07-23 Sanovel llac Sanayi Ve Ticaret Anonim Sirketi Oral film formulations comprising dapoxetine and tadalafil

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020037828A1 (en) * 1997-10-28 2002-03-28 Wilson Leland F. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US20150202168A1 (en) * 2012-08-17 2015-07-23 Sanovel llac Sanayi Ve Ticaret Anonim Sirketi Oral film formulations comprising dapoxetine and tadalafil

Also Published As

Publication number Publication date
EP3723743A2 (en) 2020-10-21
WO2019203753A3 (en) 2020-01-16
WO2019203753A2 (en) 2019-10-24

Similar Documents

Publication Publication Date Title
EP3741374A4 (en) Mtor inhibitor, pharmaceutical composition and use thereof
EP3805264A4 (en) Anti-interleukin-17a antibody, pharmaceutical composition thereof and use thereof
EP3749317A4 (en) Alpha polyglutamated pemetrexed and uses thereof
EP3782998A4 (en) Substituted pyrrolotriazine compound, pharmaceutical composition thereof and use thereof
EP3965772A4 (en) Pharmaceutical composition containing brexanolone, ganaxolone, or zuranolone, and use thereof
EP3680331A4 (en) Modified cas9 protein, and use thereof
EP3802562A4 (en) New pharmaceutical use
EP3421038A4 (en) Naphthyridine compound, pharmaceutical composition and use thereof
EP4061941A4 (en) Retrotransposons and use thereof
SG11201908281VA (en) Phenalene-1-one-containing photosensitizer composition, phenalene-1-one compound and the use thereof
EP3685828A4 (en) Ophthalmic pharmaceutical composition, ophthalmic kit, and pharmaceutical application thereof
EP3810143A4 (en) Nadph oxidase inhibitors, pharmaceutical composition comprising the same, and application thereof
EP3731837A4 (en) The combination comprising linagliptin and metformin
EP3580288A4 (en) A coating composition, the preparation method therefore and use thereof
EP3770148A4 (en) Receptor inhibitor, pharmaceutical composition comprising same, and use thereof
EP3723743A4 (en) The pharmaceutical combination comprising dapoxetine, phosphodiesterase type-5 inhibitor and anti-emetic agent
GB2606804B (en) Benzenesulfonamide derivatives and uses thereof
EP3856242A4 (en) Anti-siglec antibody, pharmaceutical composition comprising the same, and uses thereof
SG11202101435XA (en) ANTIBODY AGAINST IL-1ß, PHARMACEUTICAL COMPOSITION AND USE THEREOF
EP3904429A4 (en) Cellulose powder, use thereof, and tablet
EP3719010A4 (en) Aromatic compound, pharmaceutical composition thereof and use thereof
EP3694519A4 (en) The pharmaceutical combination comprising dapoxetine and phosphodiesterase type-5
EP3999056A4 (en) Pharmaceutical combination and use thereof
WO2017173302A3 (en) Inhibitors of integrin alpha 5 beta 1 and methods of use
EP3715344A4 (en) 1,4-benzodiazapin-2-one derivatives and use thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200323

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: TUERKYILMAZ, ALI.

Inventor name: PALATOEKEN, ARZU.

Inventor name: GUENER, DICLE.

A4 Supplementary search report drawn up and despatched

Effective date: 20210811

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/166 20060101ALI20210805BHEP

Ipc: A61K 31/519 20060101ALI20210805BHEP

Ipc: A61K 31/4985 20060101ALI20210805BHEP

Ipc: A61K 9/20 20060101ALI20210805BHEP

Ipc: A61K 31/138 20060101AFI20210805BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220311